Sulfur mustard (SM) is a blister agent with cytotoxic mechanism of action. There is no suitable treatment based on administration of an antidote. In this study, Wistar rats were exposed to SM in doses of 0-40 mg/kg body weight and treated with the compound HI-6. The treatment provided no significant effect on ferric reducing antioxidant power of blood and plasma. However, HI-6 caused an increase in the level of thiobarbituric acid reactive substances. This stressogenic response was presumably the cause of the significant elevation of the blood level of both glutathione reductase and reduced glutathione. HI-6 appears to be suitable for enhancing prophylactically oxidative stress protection from small oxidative insult
Bhattacharya R, Rao PV, Pant SC, Kumar P, Tulsawani RK, Pathak U, Kulkami A, Vijayaraghavan R. (2001). Protective eff ects of amifostine and its analogues on sulfur mustard toxicity in vitro and in vivo. Toxicol Appl Pharmacol 176: 24-33.
Bogavac M, Lakic N, Simin N, Nikoilc A, Sudji J, Boin B. (2012). Biomarkers of oxidative stress in amniotic fl uid and complications in pregnancy. J Matern Fetal Neonatal Med 25(1): 104-108.
Catala A. (2011). Lipid peroxidation of membrane phospholipids in the vertebrate retina. Front Biosci 3: 52-60.
Chen HC, Bai DY, Jiang YP. (1996). Eff ects of HI-6 on muscle acetylcholine receptor: analysis on minimal reaction model. Zhongguo Yao Li Xue Bao 17: 428-431.
Collins A, Oscoz1 AA, Brunborg G, Gaiva I, Giovannelli L, Kruszewski M, Smith C, Stetina R. (2008). The comet assay: topical issues. Mutagenesis 23: 143-151.
Gautam A, Gupta A, Lomash V, Pant SC, Vijayaraghavan R. (2010). Prophylactic effi cacy of combination of DRDE-07 and its analogues with amifostine against sulphur mustard induced systemic toxicity. Indian J Exp Biol 48: 752-761.
Gautam A, Vijayaraghavan R. (2007). Prophylactic eff ect of gossypin against percutaneously administered sulfur mustard. Biomed Environ Sci 20: 250-259.
Korkamaz A, Kunak ZI, Paredes SD, Yaren H, Tan DX, Reiter RJ. (2008b). The use of melatonin to combat mustard toxicity. Neuroendocrinol Lett 29: 614-619.
Korkmaz A, Yaren H, Kunak Z, Uysal B, Kurt B, Topal T, Kenar L, Ucar E, Oter S. (2008a). Epigenetic perturbations in the pathogenesis of mustard toxicity; hypothesis and preliminary results. Interdiscip Toxicol 1: 236-241.
Oke SL, Tracey KJ. (2009). The infl ammatory refl ex and the role of complementary and alterantive medical therapies. Ann NY Acad Sci 1172: 172-180.
Paromov V, Suntres Z, Smith M, Stone WL. (2007). Sulfur mustard toxicity following dermal exposure: role of oxidative stress, and antioxidant therapy. J Burns Wounds 7: e7.
Pohanka M. (2011). Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Olomouc 155: 219-230.
Pohanka M. (2012). Alpha7 nicotinic acetylcholne receptor is a target in pharmacology and toxicology. Int J Mol Sci 13: 2219-2238.
Pohanka M, Sobotka J, Stetina R. (2011a). Sulfur mustard induced oxidative stress and its alteration by epigallocatechin gallate. Toxicol Lett 201: 105-109.
Pohanka M, Sobotka J, Svobodova H, Stetina R. (2011b). Investigation of oxidative stress in blood, brain, kidney, and liver after oxime antidote HI-6 application in a mouse experimental model. Drug Chem Toxicol 34: 255-260.
Pohanka M, Sobotka J, Jilkova M, Stetina R. (2011c). Oxidative stress after sulfur mustard intoxication and its reduction by melatonin: effi cacy of antioxidant therapy during serious intoxication. Drug Chem Toxicol 34: 85-91.
Shohrati M, Ghanei M, Shamspour N, Babaei F, Abadi MN, Jafari M, Harandi AA. (2009). Glutathione and malondialdehyde levels in late pulmonary complications of sulfur mustard intoxication. Lung 188: 77-83.
Shohrati M, Ganei M, Shamspour N, Jafari M. (2008). Activity and function in lung injuries due to sulphur mustard. Biomarkers 13: 728-733.
Tewari-Singh N, Agarwal C, Huang J, Day BJ, White CW, Agarwal R. (2011). Effi - cacy of glutathione in ameliorating sulfur mustard analog-induced toxicity in cultured skin epidermal cells and in SKH-1 mouse skin in vivo. J Pharmacol Exp Ther 336: 450-459.
Wagner S, Kufl eitner J, Zensi A, Dadparvar M, Wien S, Bungert J, Vogel T, Worek F, Kreiter J, von Briesen H. (2010). Nanoparticulate transport of oximes over an in vitro blood-brain barrier model. PLoS One 5: e14213.